A review of rabeprazole in the treatment of acid-related diseases

References

• AdachiKHashimotoTHamamotoNSymptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazoleJ Gastroenterol Hepatol2003181392814675268
   PubMed Web of Science ®Google Scholar
• AdachiKKatsubeTKawamuraACYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazoleAliment Pharmacol Ther20001412596611012469
   PubMed Web of Science ®Google Scholar
• AndoTKatoHSugimotoNA comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differencesDig Dis Sci20055016253116133961
   PubMed Web of Science ®Google Scholar
• ArchimandritisAJNikolopoulouVKouklakisGEffects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance studyCurr Med Res Opin2005216031015899110
   PubMed Web of Science ®Google Scholar
• BarthJPerdomoCSloanSRabeprazole maintains GERD healing in patients with Barrett’s esophagusAm J Gastroenterol1999942579
   Google Scholar
• BellNJBurgetDHowdenCWAppropriate acid suppression for the management of gastro-oesophageal reflux diseaseDigestion199251Suppl 159671397746
   PubMed Web of Science ®Google Scholar
• BesanconMSimonASachsGSites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagentsJ Biol Chem199727222438469278394
   PubMed Web of Science ®Google Scholar
• BirbaraCBreiterJPerdomoCRabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study GroupEur J Gastroenterol Hepatol2000128899710958216
   PubMed Web of Science ®Google Scholar
• BourBStaubJLChoustermanMLong-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatmentAliment Pharmacol Ther2005218051215801915
   PubMed Web of Science ®Google Scholar
• Bruley Des VarannesSGharibHBichelerVEffect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjectsAliment Pharmacol Ther20042089990715479362
   PubMed Web of Science ®Google Scholar
• BurgetDWChivertonSGHuntRHIs there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppressionGastroenterology199099345512142113
   PubMed Web of Science ®Google Scholar
• BytzerPBlumADe HerdtDSix-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux diseaseAliment Pharmacol Ther200420181815233698
   PubMed Web of Science ®Google Scholar
• CaosABreiterJPerdomoCLong-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United StatesAliment Pharmacol Ther20052219320216091056
   PubMed Web of Science ®Google Scholar
• CaosAMoskovitzMDayalYRabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux diseaseAm J Gastroenterol2000953081811095321
   PubMed Web of Science ®Google Scholar
• CarswellCIGoaKLRabeprazole: an update of its use in acid related disordersDrugs20016123275611772142
   PubMed Web of Science ®Google Scholar
• CatalanoFTerminellaCBranciforteGEradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcerDigestion200266154912481161
   PubMed Web of Science ®Google Scholar
• DamianoASiddiqueRXuXReductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazoleDig Dis Sci2003486576212741452
   PubMed Web of Science ®Google Scholar
• De MilitoAFaisSProton pump inhibitors may reduce tumour resistanceExpert Opin Pharmacother2005610495415957961
   PubMed Web of Science ®Google Scholar
• DeanBBSiddiqueRMYamashitaBDCost-effectiveness of proton pump inhibitors for maintenance therapy of erosive reflux esophagitisAm J Health Syst Pharm20015813384611471482
   PubMed Web of Science ®Google Scholar
• DekkersCPBekerJAThjodleifssonBDouble-blind comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study GroupAliment Pharmacol Ther19991349579892879
   PubMed Web of Science ®Google Scholar
• Di MarioFDal BoNAragonaGRabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosagesJ Gastroenterol Hepatol200318783612795749
   PubMed Web of Science ®Google Scholar
• DickmanREmmonsSCuiHThe effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trialAliment Pharmacol Ther2005225475516167971
   PubMed Web of Science ®Google Scholar
• DuboisDHughesDABodgerKEconomic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux diseasePharmacoeconomics20052310314116235976
   PubMed Web of Science ®Google Scholar
• FarleyAWrubleLDHumphriesTJRabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study GroupAm J Gastroenterol2000951894910950032
   PubMed Web of Science ®Google Scholar
• FassROfmanJJGastroesophageal reflux disease: should we adopt a new conceptual framework?Am J Gastroenterol2002971901912190152
   PubMed Web of Science ®Google Scholar
• FeldmanMBurtonMEHistamine H2-receptor antagonistsN Engl J Med19903231672801978250
   PubMed Web of Science ®Google Scholar
• FletcherJWirzAYoungJVallanceRMcCollKEUnbuffered highly acidic gastric juice exists at the gastroesophageal junction after a mealGastroenterology20011217758311606490
   PubMed Web of Science ®Google Scholar
• FockKMTeoEKAngTLRabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban AsiaWorld J Gastroenterol2005113091815918196
   PubMed Web of Science ®Google Scholar
• FuhrUJetterARabeprazole: pharmacokinetics and pharmacokinetic drug interactionsPharmazie20025759560112369444
   PubMed Web of Science ®Google Scholar
• FurutaTShiraiNSugimotoMInfluence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapiesDrug Metab Pharmacokinet2005201536715988117
   PubMedGoogle Scholar
• GambaroCBilardiCDulbeccoPComparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a prelimary studyDig Liv Dis2003357637
   Web of Science ®Google Scholar
• GardnerJDGallo-TorresHSloanSThe basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitisAliment Pharmacol Ther20031889190514616153
   PubMed Web of Science ®Google Scholar
• GersonLBShetlerKTriadafilopoulosGControl of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett’s oesophagusDig Liv Dis2005376518
   Web of Science ®Google Scholar
• GianniniEGBilardiCDulbeccoPA study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradicationAliment Pharmacol Ther200623281716393308
   PubMed Web of Science ®Google Scholar
• GianniniEGMalfattiFBottaFInfluence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin and metronidazole on 13C-aminopyrine breath testDig Dis Sci20055012071316047461
   PubMed Web of Science ®Google Scholar
• GibsonPGHenryRLCoughlanJLGastro-oesophageal reflux treatment for asthma in adults and childrenThe Cochrane Database of Systematic Reviews2003Issue 1 Art. No.: CD001496. DOI: 10.1002/14651858.CD001496
   Google Scholar
• GisbertJPKhorramiSCalvetXSystematic review: rabeprazole-based therapies in Helicobacter pylori eradicationAliment Pharmacol Ther2003177516412641497
   PubMed Web of Science ®Google Scholar
• GisbertJPPajaresJMSystematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?Aliment Pharmacol Ther20052179580415801914
   PubMed Web of Science ®Google Scholar
• HallJDoddSDurkinMAn impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costsManaged Care200211Suppl 714812181872
   PubMedGoogle Scholar
• HoltmannGBytzerPMetzMA randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux diseaseAliment Pharmacol Ther2002164798511876701
   PubMed Web of Science ®Google Scholar
• HornJReview article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazoleAliment Pharmacol Ther200420Suppl 611915496214
   PubMed Web of Science ®Google Scholar
• HuntRHArmstrongDJamesCEffect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteersAm J Gastroenterol200510019495616128938
   PubMed Web of Science ®Google Scholar
• InamoriMTogawaJTakahashiKComparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?J Gastroenterol Hepatol2003181034812911659
   PubMed Web of Science ®Google Scholar
• IshizakiTHoraiYReview article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazoleAliment Pharmacol Ther199913Suppl 3273610491726
   PubMed Web of Science ®Google Scholar
• ItagakiFHommaMTakaraKEffect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cellsBiol Pharm Bull2004271694615467223
   PubMed Web of Science ®Google Scholar
• JaworskiTSarosiekISostarichSRestorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significanceDig Dis Sci2005503576515745101
   PubMed Web of Science ®Google Scholar
• JiSKimHSKimJWComparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseasesJ Gastroenterol Hepatol20061716706799
   PubMed Web of Science ®Google Scholar
• JohnssonFMoumBVilienMOn-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazoleScand J Gastroenterol200237pag6427
   Web of Science ®Google Scholar
• JohansonJFSiddiqueRDamianoAMRabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux diseaseDig Dis Sci2002472574812452397
   PubMed Web of Science ®Google Scholar
• JohnstonMHEastoneJAHorwhatJDCryoablation of Barrett’s esophagus: a pilot studyGastrointest Endosc200562842816301023
   PubMed Web of Science ®Google Scholar
• KahrilasPJMinerPJohansonJEfficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux diseaseDig Dis Sci20055020091816240208
   PubMed Web of Science ®Google Scholar
• KawabataHHabuYTomiokaHEffect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycinAliment Pharmacol Ther2003172596412534411
   PubMed Web of Science ®Google Scholar
• KiviojaALinnosmaaIVehvilainenACost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusionsEur J Pharm Sci200421171814757488
   PubMed Web of Science ®Google Scholar
• KlopockaMSinkiewiczABudzynskiJImprovement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazoleMed Sci Monit200410PI115815448612
   PubMed Web of Science ®Google Scholar
• KromerWKrugerUHuberRDifferences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlatesPharmacology19985657709494064
   PubMed Web of Science ®Google Scholar
• LewEABarbutiRCKovacsTOAn ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810)Aliment Pharmacol Ther199812667729701531
   PubMed Web of Science ®Google Scholar
• LuoJYNiuCYWangXQEffect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitudeWorld J Gastroenterol20039112583614606102
   PubMed Web of Science ®Google Scholar
• Mat SaadAZCollinsNLoboMMProton pump inhibitors: a survey of prescribing in an Irish general hospitalInt J Clin Pract20055931415707461
   PubMed Web of Science ®Google Scholar
• McCollKELKennerleyPProton pump inhibitors – differences emerge in hepatic metabolismDig Liv Dis2002344617
   Web of Science ®Google Scholar
• McGowanBBennettKTilsonLCost-effective prescribing of proton pump inhibitors (PPI’s) in the GMS SchemeIr Med J200598788015869064
   PubMedGoogle Scholar
• MinerPJrOrrWFilipponeJRabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trialAm J Gastroenterol2002971332912094846
   PubMed Web of Science ®Google Scholar
• OdaKIwakiriRHaraMDysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitorDig Dis Sci2005501921616187198
   PubMed Web of Science ®Google Scholar
• OfmanJJDornGHFennertyMBThe clinical and economic impact of competing management strategies for gastro-oesophageal reflux diseaseAliment Pharmacol Ther2002162617311860409
   PubMed Web of Science ®Google Scholar
• OfmanJJYamashitaBDSiddiqueRMCost-effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitisAm J Manag Care200069051611186502
   PubMed Web of Science ®Google Scholar
• OhningGVWalshJHPisegnaJRRabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjectsAliment Pharmacol Ther20031711091412752347
   PubMed Web of Science ®Google Scholar
• OribeYFujimuraMKitaTAttenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigsClin Exp Allergy200535262715784101
   PubMed Web of Science ®Google Scholar
• OrrWCGoodrichSRobertJThe effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal refluxAliment Pharmacol Ther200521103815679759
   PubMed Web of Science ®Google Scholar
• PaceFAnneseVPradaARabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomized, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux, followed by a maintenance open-label, low-dose therapy with rabeprazoleDig Liver Dis2005377415016024305
   PubMedGoogle Scholar
• PaceFBianchi-PorroGGastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed)Am J Gastroenterol200499946915128365
   PubMed Web of Science ®Google Scholar
• PaceFPallottaSBianchi PorroGOn demand proton pump therapy in patients with gastro-esophageal reflux diseaseDig Liver Dis200234870712643297
   PubMedGoogle Scholar
• PantoflickovaDDortaGRavicMAcid inhibition on the first day of dosing: comparison of four proton pump inhibitorsAliment Pharmacol Ther20031715071412823153
   PubMed Web of Science ®Google Scholar
• PehlivanovNDOlyaeeMSarosiekIComparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over studyAliment Pharmacol Ther2003188839014616152
   PubMed Web of Science ®Google Scholar
• PonceJArguelloLBastidaGOn-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfactionDig Dis Sci200449931615309880
   PubMed Web of Science ®Google Scholar
• RemakEBrownREYuenCCost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UKCurr Med Res Opin20052115051716238890
   PubMed Web of Science ®Google Scholar
• RielMAKyleDEBhattacharjeeAKEfficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophoresAntimicrob Agents Chemother20024626273212121943
   PubMed Web of Science ®Google Scholar
• RobinsonMFitzgeraldSHegedusROnset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitisAliment Pharmacol Ther2002164455411876697
   PubMed Web of Science ®Google Scholar
• SaitohTFukushimaYOtsukaHEffects or rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizersAliment Pharmacol Ther2002161811712269976
   PubMed Web of Science ®Google Scholar
• SakaiTAoyamaNKitaTCYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjectsPharm Res200118721711474773
   PubMed Web of Science ®Google Scholar
• SarelaAIHickDGVerbekeCSPersistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapyArch Surg20041395475115136356
   PubMedGoogle Scholar
• ShimataniTInoueMKuroiwaTAcid-suppressive effects of rabeprazole, omeprazole and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19Clin Pharmacol Ther2006791445216413249
   PubMed Web of Science ®Google Scholar
• ShiraiNFurutaTMoriyamaYEffects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pHAliment Pharmacol Ther20011519293711736724
   PubMed Web of Science ®Google Scholar
• SkoczylasTSarosiekISostarichSSignificant enhancement of gastric mucin content after rabeprazole administration. Its potential clinical significance in acid-related disordersDig Dis Sci200348322812643610
   PubMed Web of Science ®Google Scholar
• SloanSRabeprazole-based therapy in the management of symptomatic gastroesophageal reflux diseaseAm J Gastroenterol2003983 SupplS49S5512644031
   PubMed Web of Science ®Google Scholar
• StewardDLWilsonKMKellyDHProton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trialOtolaryngol Head Neck Surg20041313425015467597
   PubMed Web of Science ®Google Scholar
• SwanSKHoyumpaAMMerrittGJReview article: the pharmacokinetics of rabeprazole in health and diseaseAliment Pharmacol Ther199913Suppl 311710491724
   PubMed Web of Science ®Google Scholar
• SwiatkowskiMBudzynskiJKlopockaMSuppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery diseaseMed Sci Monit200410CR524915328486
   PubMed Web of Science ®Google Scholar
• ThjodleifssonBCockburnIReview article: rabeprazole’s tolerability profile in clinical trialsAliment Pharmacol Ther199913Suppl 5172310555605
   PubMed Web of Science ®Google Scholar
• ThjodleifssonBRindiGFioccaRA randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 yearsAliment Pharmacol Ther2003173435112562446
   PubMed Web of Science ®Google Scholar
• ThjodleifssonBReview of rabeprazole in the treatment of gastro-oesophageal reflux diseaseExpert Opin Pharmacother200451374914680443
   PubMed Web of Science ®Google Scholar
• ThjodleifssonBBekerJADekkersCRabeprazole vs omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double blind multicenter European trial. The European Rabeprazole Study GroupDig Dis Sci2000458455310795744
   PubMed Web of Science ®Google Scholar
• TolmanKGTäubelJWarringtonSComparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteersClin Drug Invest200626218
   Web of Science ®Google Scholar
• TsugenoHMizunoMFujikiSA proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal refluxScand J Gastroenterol2003384566112795453
   PubMed Web of Science ®Google Scholar
• VakilNLanzaFSchwartzHSeven-day therapy for Helicobacter pylori in the United StatesAliment Pharmacol Ther2004209910715225176
   PubMed Web of Science ®Google Scholar
• Van HerwaardenMASamsonMSmoutAJHelicobacter pylori eradication increases nocturnal acid breakthroughAliment Pharmacol Ther200014961210886054
   PubMed Web of Science ®Google Scholar
• VoLSimonianHPDomaSThe effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled studyAliment Pharmacol Ther20052113213015932362
   PubMed Web of Science ®Google Scholar
• WangHChouJLiaoKOne-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapyWorld J Gastroenterol2005111680415786549
   PubMed Web of Science ®Google Scholar
• WaniSSamplinerREWestonAPLack of predictors of normalization of oesophageal acid exposure in Barrett’s oesophagusAliment Pharmacol Ther2005226273316181302
   PubMed Web of Science ®Google Scholar
• WarringtonSBaisleyKBoyceMEffects of rabeprazole 20 mg, or esomeprazole 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjectsAliment Pharmacol Ther2002161301712144580
   PubMed Web of Science ®Google Scholar
• WilliamsMPSercombeJHamiltonMIA placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjectsAliment Pharmacol Ther1998121079899845397
   PubMed Web of Science ®Google Scholar
• WitNJBoerWAGeldofHTreatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?Aliment Pharmacol Ther200420451815298640
   PubMed Web of Science ®Google Scholar
• WongBCYWongWMYeeYKRabeprazole-based 3-day and 7-day triple therapy vs omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infectionAliment Pharmacol Ther20011519596511736727
   PubMed Web of Science ®Google Scholar
• YangKWangGChenJComparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcerJ Formos Med Assoc20031028576214976565
   PubMed Web of Science ®Google Scholar